about
The β-Lactamase Assay: Harnessing a FRET Biosensor to Analyse Viral Fusion MechanismsInvolvement of Ceramide in the Propagation of Japanese Encephalitis VirusInduction of membrane ceramides: a novel strategy to interfere with T lymphocyte cytoskeletal reorganisation in viral immunosuppression.Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alphaBiofluid lipidome: a source for potential diagnostic biomarkers.The Role of Lipids in Retrovirus Replication.Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane.Identification of an overabundant cholesterol precursor in hepatitis B virus replicating cells by untargeted lipid metabolite profilingRole of sphingolipids in microbial pathogenesisSphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages.Sphingomyelin synthase 2, but not sphingomyelin synthase 1, is involved in HIV-1 envelope-mediated membrane fusion.HIV entry and envelope glycoprotein-mediated fusionTargeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.Neutral sphingomyelinase in physiological and measles virus induced T cell suppression.Sphingosine kinase 1 serves as a pro-viral factor by regulating viral RNA synthesis and nuclear export of viral ribonucleoprotein complex upon influenza virus infection.A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infectionsHigh-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry InhibitorsSphingomyelinase restricts the lateral diffusion of CD4 and inhibits human immunodeficiency virus fusionRapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils.Restricted lateral mobility of plasma membrane CD4 impairs HIV-1 envelope glycoprotein mediated fusionSphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1Lipidomics of host-pathogen interactions.CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development.The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides.Ceramide activates JNK to inhibit a cAMP-gated K+ conductance and Cl- secretion in intestinal epithelia.Measles virus-induced immunosuppression: from effectors to mechanisms.Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.Role of lipids in virus replicationCytoskeletal dynamics: concepts in measles virus replication and immunomodulation.Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex.Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.Host sphingolipid biosynthesis as a target for hepatitis C virus therapy.Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels.Sphingosine kinase 1 regulates measles virus replication.Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane StructureA Robust Liposomal Platform for Direct Colorimetric Detection of Sphingomyelinase Enzyme and Inhibitors
P2860
Q26747003-8D53AC15-C988-45F3-A373-9E5D662F2C1EQ27490958-9F390B84-43B6-46AA-9E22-F8D46225AA44Q33510915-5B91F722-47D5-4C2C-8747-6B5359C28C65Q33815944-C191412B-8205-4FB5-82E2-92C64108B74CQ33822645-617B0E9C-C770-405C-B376-4B236F52B7A6Q34080779-0F1B7EEE-47EC-4E61-8937-95B28C29E09CQ34148120-DF6F8ECB-CD5A-4A9E-A770-798057B2D6D1Q34199965-512B84B6-E6CC-4AAC-B988-AECDAB88F6B4Q34300991-B741CCF1-DE46-4344-A9FB-50BF349329F1Q34401169-DFE7E94D-553F-47AC-A054-66248C443ACBQ34431138-D7CE0D21-299F-4054-AF8D-1EDF1A3DE3EAQ34435855-91C4789F-5476-4173-9F79-264B4A1BA6D7Q34568549-F89C852B-D9F3-4128-9516-E275E5096C0AQ34734221-AF54F1B6-B39F-4DF1-8060-D7089468D86AQ35020246-429DF288-B427-4569-932D-88FEF5A50F47Q35472380-1CD753F0-3C9C-4C46-86DC-75A0457F4571Q35600803-8F5FD4AC-E077-4F8A-832E-B0118087765AQ35857576-35D2B304-7FCA-4084-B5F7-80F468C00D02Q35878870-E652503B-3164-41A1-AF23-5062E0499C09Q36090859-5F88DE92-074E-437E-A656-64FD9731FF05Q36303032-E03D6D97-F551-4A74-9756-A159449700DCQ36329809-882B11BB-29FF-4DCD-96A8-2DDFB1165691Q36543297-FD576FBB-5436-44C4-96BA-D2D136F5D05EQ36553987-EA8F4F63-B709-4CFA-BF61-C19612AD565AQ36798434-2964B3C3-AC60-45A0-B5FF-1B49D5F6597FQ36879383-35C5DE72-2766-4621-9693-3E268122EB6FQ36949766-986EDA51-9F91-408C-862A-46E91A23A093Q37061677-05FB947E-5251-469F-A611-1C428DA2C892Q37727048-E946B33B-A030-4743-BCEA-CFBEEAE7CD58Q37858901-E6CFFAD9-02C6-4179-9A65-06BE77F3F4BCQ37882865-65493086-2628-4040-9111-C8EEEC45E73FQ37952177-70982243-8069-4C92-A463-0591C9197133Q38818977-A0301DB7-08E2-4A2A-A34D-F05B17FB2FB5Q40057653-50F52DCB-28FB-4896-A394-C1B44DE02C4DQ40330820-244CE652-1D0B-42C8-ABE5-EEFAD86BFBA8Q40700090-16553640-3D05-4C83-BE72-D68BC1621671Q41934199-7F959031-70C0-480E-8201-50B777623A29Q57008156-0E60407A-CC05-43C9-A59E-61B22F59E4B6Q58798571-DBE9C07E-3D62-4CDA-BB1C-4EFCE014A8CC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ceramide, a target for antiretroviral therapy.
@en
Ceramide, a target for antiretroviral therapy.
@nl
type
label
Ceramide, a target for antiretroviral therapy.
@en
Ceramide, a target for antiretroviral therapy.
@nl
prefLabel
Ceramide, a target for antiretroviral therapy.
@en
Ceramide, a target for antiretroviral therapy.
@nl
P2093
P2860
P356
P1476
Ceramide, a target for antiretroviral therapy.
@en
P2093
Catherine M Finnegan
Francis W Ruscetti
Ji Ming Wang
Robert Blumenthal
Satinder S Rawat
P2860
P304
15452-15457
P356
10.1073/PNAS.0402874101
P407
P577
2004-10-15T00:00:00Z